 The FDA has granted Breakthrough Designation to NeuroMetrix Incs NASDAQ:NURO Quell technology for reducing moderate to severe symptoms of chemotherapy-induced peripheral neuropathy CIPN that have persisted for at least 6-months following the end of chemotherapy. There are no FDA-approved treatments for CIPN, and those that are used have limited effectiveness and have side effects. 